analysis-based-on-tcga-data-single-cell-data-taking-trpm4-as-an

Analysis Based on TCGA Data and Single-cell Data, taking <em>TRPM4</em> as an Example

In this article, an analysis method is introduced based on public transcriptomic datasets and single-cell datasets, which could be used to comprehensively ...

Nanjing Medical University

Myocardial infarction (MI) causes cardiac dysfunction and threatens global health. Timely reperfusion following MI unavoidably contributes to additional cardiomyocyte death, a phenomenon known as myocardial ischemia/reperfusion injury (I/RI). The surge in free radicals and extensive cardiomyocyte loss significantly promote the progression toward heart failure, a condition that remains a major therapeutic challenge. Development of microRNA (miRNA)-based therapeutics for I/RI is hindered by poor intracellular delivery of miRNA and its rapid degradation in vivo. Nanozymes with enzyme-mimetic activities offer promising platforms for miRNA delivery while concurrently mitigating oxidative stress. Hollow ceria nanozymes decorated with gold nanoparticles (AuNPs) are developed to deliver miR-486, whose cavernous rooms enable them to accommodate miRNA. Elevated miR-486 expression is shown to suppress myocardial apoptosis and alleviate I/RI. Equipped with cardiac target peptide, miR-486@CeO/Au-pep nanoparticles are integrated with superior enzyme-mimicking functions than a single entity, reactive oxygen species (ROS) scavenging, and improved miR-486 delivery. In myocardial I/RI mice, miR-486@CeO/Au-pep can specifically accumulate at the heart and promote miR-486 to escape from lysosomes, which further boosts the bioactivity of miR-486 in cardiomyocytes. These combined effects confer cardioprotection and inhibit adverse ventricle remodeling. The nanosystem through synergetic works of miRNA and nanozymes provides an effective approach to treating myocardial I/RI.

Cascade Nanozyme Delivering miRNA to Ischemic Heart to Alleviate Myocardial Ischemia-Reperfusion Injury.

Bladder cancer (BLCA) is one of the most invasive and malignant tumors in the world, thus leading to the urgent need of an accurate and recognizable biomarker. Several previous research has shown that Transient Receptor Potential Melastatin 4 (TRPM4) plays an important role in measuring vascular fragility and endothelial function. However, the role of TRPM4 in tumor hasn't been explored.

Article	Year
Cascade Nanozyme Delivering miRNA to Ischemic Heart to Alleviate Myocardial Ischemia-Reperfusion Injury. Small (Weinheim an der Bergstrasse, Germany)\| PubMed ID: 40289785	2025
Transient Receptor Potential Melastatin 4 (TRPM4) is associated with an immuno-stimulatory TME and better prognosis in BLCA. Discover oncology\| PubMed ID: 41266683	2025

Xuerui Chen

Biography

JoVE Journal Publications

Other Publications